Skip to main content
. 2020 Jul 28;11:1505. doi: 10.3389/fimmu.2020.01505

Table 1.

Patient characteristics.

Chronic GVHD
Characteristics No (n = 42) Active (n = 42) P
Age, median (range), y 30 (16–61) 30 (17–57) 0.83
Gender, no (%) 0.35
    Male 31 (73.8) 26 (61.9)
    Female 11 (26.2) 16 (38.1)
Primary disease, no (%)a 0.17
    ALL 15 (35.7) 23 (54.7)
    AML 24 (57.1) 18 (42.9)
    Others 3 (7.2) 1 (2.4)
Duration time from HSCT to sample
collection, median (range), m
8.7 (3.1–21.1) 8.9 (3.4–19.2) 0.98
Conditioning regimen, no (%)b 0.59
    Myeloablative 35 (83.3) 32 (76.2)
    Intensified 7 (16.7) 10 (23.8)
HLA typing, no (%) 0.37
    Matched 24 (57.1) 29 (69.0)
    Mismatched 18 (42.9) 13 (31.0)
Source of graft, no (%) 0.12
    BM + PBSC 22 (52.4) 14 (33.3)
    PBSC 20 (47.6) 28 (66.7)
GVHD prophylaxis, no (%)c <0.01
    ATG based 27 (64.3) 13 (31.0)
    Non-ATG based 15 (35.7) 29 (69.0)
Acute GVHD grade, no (%) 0.46
    0–I 33 (78.6) 29 (69.0)
    II–IV 9 (21.4) 13 (31.0)
Immunosuppressive treatments at
study inclusion, no (%)d
<0.001
    None 18 (42.9) 0 (0.0)
    1 24 (57.1) 10 (23.8)
    2 0 (0.0) 23 (54.8)
    ≥ 3 0 (0.0) 9 (21.4)
Duration of immunosuppressive
medication, median (range), m
3.0 (2.0–7.0) 9.0 (3.0–18.0) <0.01

GVHD, graft-vs.-host disease; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HSCT, hematopoietic stem cell transplantation; HLA, human leukocyte antigen; BM, bone marrow; PBSC, peripheral blood stem cell; ATG, antithymocyte globulin.

a

The other category included aplastic anemia, myelodysplastic syndrome, and lymphoma.

b

Myeloablative conditioning regimens include TBI (total body irradiation) + Cy (cyclophosphamide), Bu (busulfan)+ Cy, and Bu + Flu (fludarabine). Intensified conditioning regimens include TBI + Cy + etoposide, and Flu + cytarabine + TBI + Cy.

c

Non-ATG based GVHD prophylaxis include cyclosporine A (CsA), methotrexate (MTX), and mycophenolate mofetil (MMF). ATG based GVHD prophylaxis include CsA + MTX + MMF + ATG.

d

Immunosuppressive treatments include CsA, tacrolimus (Tac), MMF, and steroids.